PMID- 19657709
OWN - NLM
STAT- MEDLINE
DCOM- 20091229
LR  - 20151119
IS  - 1880-4233 (Electronic)
IS  - 1340-6868 (Linking)
VI  - 16
IP  - 4
DP  - 2009
TI  - Recent trends of HER-2 testing and trastuzumab therapy for breast cancer.
PG  - 284-7
LID - 10.1007/s12282-009-0159-z [doi]
AB  - Molecular-targeted therapy using trastuzumab, a humanized monoclonal antibody 
      against human epidermal growth factor receptor type-2 (HER-2), is considered to 
      be effective for metastatic as well as primary breast cancer and has already 
      become a worldwide standard therapy for patients with HER-2 protein 
      over-expression and gene amplification. Pretreatment evaluation of HER-2 status 
      is considered to be essential for selection of patients, and according to the 
      generally used algorithm, cases with an immunohistochemistry (IHC) score of 3+ 
      and positivity upon fluorescence in situ hybridization (FISH) are thought to be 
      eligible for trastuzumab therapy. In order to develop an appropriate domestic 
      HER-2 testing system in Japan, the Trastuzumab Pathology Committee was 
      established in 2000 and has been used as a forum for active discussions of 
      policies related to HER-2 testing. After trastuzumab therapy and HER-2 testing 
      had become widely adopted internationally, new guidelines for HER-2 testing were 
      proposed by the ASCO/CAP group in 2007. Since then, these guidelines have 
      gradually become accepted and used in many large-scale clinical studies of 
      HER-2-targeting agents. On the other hand, new ISH methods have been introduced, 
      such as bright-field HER-2 and chromosome 17 centromere double in situ 
      hybridization (BDISH) and dual color-chromogenic in situ hybridization (dc-CISH). 
      These methods make it possible to examine HER-2 gene amplification using only one 
      paraffin section like the dc-FISH method, and to observe grains on the HER-2 gene 
      and centrosome-17 by conventional microscopy. These approaches are considered to 
      be reliable and equally as effective as the dc-FISH method. Accurate evaluation 
      of HER-2 status is thought to be most important for appropriate selection of 
      breast cancer patients who will obtain genuine benefit from trastuzumab 
      treatment. In order to perform effective evaluation of HER-2 status, it is 
      necessary to establish a reliable HER-2 examination system and to maintain its 
      quality at a high level.
FAU - Kurosumi, Masafumi
AU  - Kurosumi M
AD  - Department of Pathology, Saitama Cancer Center, 818 Komuro, Ina-machi, 
      Kitaadachi-gun, Saitama 362-0806, Japan. mkurosumi@cancer-c.pref.saitama.jp
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090806
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Breast Neoplasms/*chemistry/*drug therapy
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Receptor, ErbB-2/*analysis
MH  - Trastuzumab
RF  - 11
EDAT- 2009/08/07 09:00
MHDA- 2009/12/30 06:00
CRDT- 2009/08/07 09:00
PHST- 2009/06/07 00:00 [received]
PHST- 2009/06/22 00:00 [accepted]
PHST- 2009/08/07 09:00 [entrez]
PHST- 2009/08/07 09:00 [pubmed]
PHST- 2009/12/30 06:00 [medline]
AID - 10.1007/s12282-009-0159-z [doi]
PST - ppublish
SO  - Breast Cancer. 2009;16(4):284-7. doi: 10.1007/s12282-009-0159-z. Epub 2009 Aug 6.